The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Duke University
Greer Laboratories
Information provided by (Responsible Party):
Robert A. Wood, Johns Hopkins University
ClinicalTrials.gov Identifier:
NCT00732654
First received: August 8, 2008
Last updated: March 29, 2012
Last verified: March 2012

August 8, 2008
March 29, 2012
August 2008
June 2010   (final data collection date for primary outcome measure)
The primary endpoint is clinical response to treatment, defined as (1) tolerating ten times the initial oral food challenge threshold dose, OR (2) tolerating the maximum oral food challenge dose at the oral food challenge, at completion of immunotherapy. [ Time Frame: Approximately 1 1/2 years. ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00732654 on ClinicalTrials.gov Archive Site
  • The proportion of patients who maintain a clinical response after withdrawal of treatment for one week. [ Time Frame: Approximately 1 1/2 years. ] [ Designated as safety issue: No ]
  • The proportion of patients who maintain a clinical response after withdrawal of treatment for six weeks. [ Time Frame: Approximately 1 1/2 years. ] [ Designated as safety issue: No ]
  • Incidence of all serious adverse events during the study [ Time Frame: Approximately 1 1/2 years. ] [ Designated as safety issue: Yes ]
  • Incidence of all adverse events during the study. [ Time Frame: Approximately 1 1/2 years. ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy
The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy

The purpose of this study is to determine if small oral and sublingual doses of milk protein are safe and effective in decreasing sensitivity to cow's milk in allergic children.

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Milk Allergy
  • Drug: Milk Protein Extract Immunotherapy
    Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.
  • Drug: Milk Protein Extract Immunotherapy
    Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years.
  • Drug: Milk Powder Immunotherapy
    Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.
  • Drug: Milk Powder Immunotherapy
    Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years.
  • Experimental: 1
    These subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 2000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year.
    Interventions:
    • Drug: Milk Protein Extract Immunotherapy
    • Drug: Milk Powder Immunotherapy
  • Experimental: 2
    These subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 1000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year.
    Interventions:
    • Drug: Milk Protein Extract Immunotherapy
    • Drug: Milk Powder Immunotherapy
  • Experimental: 3
    These subjects will have a dose escalation of the milk protein extract given sublingually. After dose escalation, they will continue on the sublingual daily maintenance dose for approximately one year.
    Intervention: Drug: Milk Protein Extract Immunotherapy
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
30
June 2015
June 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Are age 6 to 21 years
  • Provide signed informed consent (by parent or legal guardian if the subject is a minor), and informed assent if applicable
  • Have a history of symptomatic reactivity to cow's milk (i.e. Eczema, urticaria, upper or lower respiratory symptoms, GI disturbances, other rash or oral symptoms)
  • Have a positive skin prick test (defined as wheal 3 mm ≥ negative control) and cow's milk-IgE > 0.35 kIU/L
  • Have a positive OFC to cow's milk at a cumulative dose of less than 184 milligrams of cow's milk intact protein (2,400 mg total milk protein).
  • Are using appropriate birth control if subject is female and of child bearing age.
  • Have self-injectable epinephrine (ie. EpiPen® or EpiPen Jr.®) available at home

Exclusion Criteria:

  • Have a history of severe anaphylaxis defined as hypoxia (cyanosis or SpO2 ≤ 92% at any stage), hypotension, confusion, collapse, loss of consciousness; or incontinence
  • Have a history of intubation related to asthma
  • Tolerate more than 184 milligrams of intact cow's milk protein at initial OFC
  • Are pregnant or lactating
  • Have a viral URI or gastroenteritis within 7 days of OFC (OFC needs to be rescheduled)
  • Have pulmonary function tests <80% of predicted (FEV1) or clinical history consistent with more than moderate persistent asthma
  • Are currently taking greater than medium dose inhaled corticosteroid (>400 mcg/day fluticasone or fluticasone equivalent if ≤ 12 years old or > 600 mcg/day if > 12 years old)
  • Are unable to discontinue antihistamines for 5 days for long acting and 3 days for short acting prior to skin testing or food challenges
  • Have used systemic corticosteroids within 4 weeks prior to baseline visit
  • Are receiving omalizumab, beta-blocker, ACE inhibitor or tricyclic antidepressant therapy
  • Have a chronic disease (other than asthma, atopic dermatitis or rhinitis) requiring therapy (e.g., heart disease, diabetes)
  • Have participated in any interventional study for treatment of a food allergy in the past 12 months
  • Have a severe reaction at initial DBPCFC, defined as either:

Life-threatening anaphylaxis, or Reaction requiring hospitalization

Both
6 Years to 21 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00732654
NCT00014511
Yes
Robert A. Wood, Johns Hopkins University
Robert A. Wood
  • Duke University
  • Greer Laboratories
Principal Investigator: Robert Wood, MD Johns Hopkins University
Johns Hopkins University
March 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP